Head-to-head evidence
natalizumab vs Tyruko (natalizumab-sztn)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Crohn's Disease
Shared mechanism: α4 integrin · full Crohn's Disease pipeline
natalizumab · Tysabri
Marketed by Biogen
NCT00032799 · Phase 3 · completed
The study was large, randomized, and double-blind, but the registry snapshot does not identify the comparator arm or primary endpoint. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Tyruko (natalizumab-sztn)
Marketed by Sandoz Group AG
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Multiple Sclerosis
Shared mechanism: α4 integrin · full Multiple Sclerosis pipeline
natalizumab · Tysabri
Marketed by Biogen
NCT00027300 · Phase 3 · completed
The trial was large, randomized, blinded, and placebo-controlled, with hard clinical endpoints of relapse rate and disability progression, and natalizumab significantly reduced both (68% relapse-rate reduction and 42% reduction in sustained disability progression, both P<0.001).
Next expected readout: October 2027 · NCT05418010 (registry estimate)
Tyruko (natalizumab-sztn)
Marketed by Sandoz Group AG
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: natalizumab's landscape · Tyruko (natalizumab-sztn)'s landscape